BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Boyapati RK, Ho GT, Satsangi J. Top-down in the Long Term in Crohn's Disease. J Crohns Colitis. 2018;12:513-514. [PMID: 29548025 DOI: 10.1093/ecco-jcc/jjy027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S. American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. Gastroenterology 2017;152:277-295.e3. [PMID: 27840073 DOI: 10.1053/j.gastro.2016.10.039] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
3 Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis 2020;14:192-204. [PMID: 31504340 DOI: 10.1093/ecco-jcc/jjz137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
4 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
5 Gong J, Zhu L, Guo Z, Li Y, Zhu W, Li N, Li J. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One. 2013;8:e81487. [PMID: 24312308 DOI: 10.1371/journal.pone.0081487] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
6 Kassam Z, Belga S, Roifman I, Hirota S, Jijon H, Kaplan GG, Ghosh S, Beck PL. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis 2014;20:2483-92. [PMID: 25185685 DOI: 10.1097/MIB.0000000000000173] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
9 Regueiro MD, Mcanallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The Inflammatory Bowel Disease Specialty Medical Home: A New Model of Patient-centered Care. Inflammatory Bowel Diseases 2016;22:1971-80. [DOI: 10.1097/mib.0000000000000819] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
10 Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 15.0] [Reference Citation Analysis]
11 Vasant DH, Ford AC. Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift? World J Gastroenterol 2020; 26(26): 3712-3719 [PMID: 32774052 DOI: 10.3748/wjg.v26.i26.3712] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scandinavian Journal of Gastroenterology 2020;55:920-3. [DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis 2013;19:2625-33. [PMID: 24108113 DOI: 10.1097/01.MIB.0000437043.36338.21] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opinion on Drug Safety 2015;14:987-97. [DOI: 10.1517/14740338.2015.1029915] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sasidharan S, Yajnik V, Khalili H, Garber J, Xavier R, Ananthakrishnan AN. Genetic risk factors for serious infections in inflammatory bowel diseases. Scand J Gastroenterol 2017;52:570-6. [PMID: 28162010 DOI: 10.1080/00365521.2017.1286381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ford AC, Peyrin-biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology 2013;108:1268-76. [DOI: 10.1038/ajg.2013.138] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 25.1] [Reference Citation Analysis]
17 Nyboe Andersen N, Pasternak B, Friis-Møller N, Andersson M, Jess T. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809. [PMID: 26048617 DOI: 10.1136/bmj.h2809] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
18 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
19 Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
21 Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ; Crohn’s Colitis Foundation Clinical Research Alliance. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology 2021;160:1131-9. [PMID: 33227283 DOI: 10.1053/j.gastro.2020.11.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
22 [DOI: 10.1101/410035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Dart RJ, Griffin N, Taylor K, Duncan J, Sastrillo M, Sanderson J, Irving PM. Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol 2014;5:176-82. [PMID: 28839767 DOI: 10.1136/flgastro-2013-100392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
24 Queiroz NSF, Regueiro M. Safety considerations with biologics and new inflammatory bowel disease therapies. Curr Opin Gastroenterol 2020;36:257-64. [PMID: 31895234 DOI: 10.1097/MOG.0000000000000607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:1141-8. [PMID: 25864945 DOI: 10.1111/apt.13195] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
26 Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. Front Pharmacol 2019;10:247. [PMID: 30941038 DOI: 10.3389/fphar.2019.00247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Park J, Cheon JH. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. Gut Liver 2018;12:623-32. [PMID: 29788675 DOI: 10.5009/gnl17462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Imperatore N, Foggia M, Patturelli M, Rispo A, Calabrese G, Testa A, Pellegrini L, Tosone G, Di Luna I, Nardone OM, Ricciolino S, Castiglione F. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol 2021;36:1859-68. [PMID: 33283312 DOI: 10.1111/jgh.15367] [Reference Citation Analysis]
30 Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis 2016;22:1425-34. [PMID: 26933752 DOI: 10.1097/MIB.0000000000000738] [Cited by in Crossref: 70] [Cited by in F6Publishing: 23] [Article Influence: 17.5] [Reference Citation Analysis]
31 Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, Grainville T, Bellissant E, Siproudhis L, Bouguen G. Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. Clin Gastroenterol Hepatol 2021;19:288-295.e4. [PMID: 32200087 DOI: 10.1016/j.cgh.2020.03.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
32 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
33 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
34 Alipour O, Lee V, Tejura TK, Wilson ML, Memel Z, Cho J, Cologne K, Hwang C, Shao L. The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. Scand J Gastroenterol 2021;:1-7. [PMID: 34344243 DOI: 10.1080/00365521.2021.1958368] [Reference Citation Analysis]
35 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
36 Martins MM, Ferreira P, Maciel R, Costa C. Vulvar herpes zoster infection: a rare and challenging diagnosis. BMJ Case Rep 2021;14:e246797. [PMID: 34972780 DOI: 10.1136/bcr-2021-246797] [Reference Citation Analysis]
37 Katz S, Surawicz C, Pardi DS. Management of the Elderly Patients with Inflammatory Bowel Disease: Practical Considerations. Inflammatory Bowel Diseases 2013;19:2257-72. [DOI: 10.1097/mib.0b013e31828c8536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
38 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Bots SJ, Kuin S, Ponsioen CY, Gecse KB, Duijvestein M, D'Haens GR, Löwenberg M. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scand J Gastroenterol 2019;54:281-8. [PMID: 30907185 DOI: 10.1080/00365521.2019.1582693] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
40 Krugliak Cleveland N, Masching A, Rubin DT. Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease. ACG Case Rep J 2020;7:e00449. [PMID: 32904020 DOI: 10.14309/crj.0000000000000449] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019 [PMID: 25473153 DOI: 10.3748/wjg.v20.i43.16014] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
43 Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS One 2016;11:e0155218. [PMID: 27214202 DOI: 10.1371/journal.pone.0155218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
44 Zhang WX, Ma CY, Zhang JG, He F, Liu QM, Cheng A, Liu T, Zhang J, Wang J, Bu X, Xie Y, Diao Z, Bai J. Effects of cytomegalovirus infection on the prognosis of inflammatory bowel disease patients. Exp Ther Med 2016;12:3287-93. [PMID: 27882151 DOI: 10.3892/etm.2016.3763] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
45 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
46 Hagen JW, Pugliano-Mauro MA. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg 2018;44:469-80. [PMID: 29315147 DOI: 10.1097/DSS.0000000000001455] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
47 Buisson A, Hordonneau C, Goutte M, Scanzi J, Goutorbe F, Klotz T, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease. Digestive and Liver Disease 2016;48:260-6. [DOI: 10.1016/j.dld.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
48 Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958. [PMID: 23834232 DOI: 10.3109/00365521.2013.812141] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
49 Liu F, Wang X, Li D, Cui Y, Li X. Apple polyphenols extract alleviated dextran sulfate sodium-induced ulcerative colitis in C57BL/6 male mice by restoring bile acid metabolism disorder and gut microbiota dysbiosis. Phytother Res 2021;35:1468-85. [PMID: 33215776 DOI: 10.1002/ptr.6910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
50 Duron C, Goutte M, Pereira B, Bommelaer G, Buisson A. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. European Journal of Gastroenterology & Hepatology 2015;27:705-11. [DOI: 10.1097/meg.0000000000000354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
51 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
52 Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panés J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2021;27:816-25. [PMID: 32766762 DOI: 10.1093/ibd/izaa199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Aniwan S, Harmsen WS, Tremaine WJ, Kane SV, Loftus EV Jr. Overall and Cause-Specific Mortality of Inflammatory Bowel Disease in Olmsted County, Minnesota, From 1970 Through 2016. Mayo Clin Proc. 2018;93:1415-1422. [PMID: 30293558 DOI: 10.1016/j.mayocp.2018.03.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
54 Seicean A, Moldovan-Pop A, Seicean R. Ulcerative colitis worsened after Clostridium difficile infection: Efficacy of infliximab. World J Gastroenterol 2014; 20(17): 5135-5140 [PMID: 24803831 DOI: 10.3748/wjg.v20.i17.5135] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
56 Hissong E, Chen Z, Yantiss RK. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence. Mod Pathol 2019;32:1210-6. [DOI: 10.1038/s41379-019-0258-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Aardoom MA, Joosse ME, de Vries ACH, Levine A, de Ridder L. Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis 2018;24:732-41. [PMID: 29522170 DOI: 10.1093/ibd/izx104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
58 Vaisman A, Pivovarov K, McGeer A, Willey B, Borgundvaag B, Porter V, Gnanasuntharam P, Wei Y, Nguyen GC. Prevalence and incidence of antimicrobial-resistant organisms among hospitalized inflammatory bowel disease patients. Can J Infect Dis Med Microbiol 2013;24:e117-21. [PMID: 24489571 DOI: 10.1155/2013/609230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
59 Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110. [PMID: 23860567 DOI: 10.1097/MIB.0b013e31829936c2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 9.4] [Reference Citation Analysis]
60 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017;15:376-384.e5. [PMID: 27189912 DOI: 10.1016/j.cgh.2016.05.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
61 Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854-863. [PMID: 23981095 DOI: 10.1111/apt.12464] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
62 Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy 2015;35:412-23. [PMID: 25884529 DOI: 10.1002/phar.1561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
63 Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther 2019;19:89-98. [PMID: 30571147 DOI: 10.1080/14712598.2019.1561850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
64 Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2013;7:549-58. [PMID: 23985004 DOI: 10.1586/17474124.2013.824693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25:831-842. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
66 Hazenberg HMJL, de Boer NKH, Mulder CJJ, Mom SH, van Bodegraven AA, Tack Md PhD GJ. Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. Inflamm Bowel Dis. 2018;24:510-531. [PMID: 29462389 DOI: 10.1093/ibd/izx062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
67 Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis 2019;25:998-1005. [PMID: 30590558 DOI: 10.1093/ibd/izy376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
68 Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
69 Adedokun OJ, Xu Z, Marano C, O’brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2244-2255.e9. [DOI: 10.1016/j.cgh.2019.11.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
70 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443-1451; quiz e88-9. [PMID: 24462626 DOI: 10.1016/j.cgh.2014.01.021] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 11.8] [Reference Citation Analysis]
71 Côté-Daigneault J, Peerani F, MacMahon E, Delaporte E, Rahier JF, Colombel JF. Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary. Inflamm Bowel Dis 2016;22:2538-47. [PMID: 27598743 DOI: 10.1097/MIB.0000000000000902] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
72 Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:453-60. [PMID: 28129288 DOI: 10.1097/MIB.0000000000001021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
73 Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M; SIGENP IBD Working Group. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics 2019;13:13-21. [PMID: 30655661 DOI: 10.2147/BTT.S183088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Cassim S, Bilodeau M, Vincent C, Lapierre P. Novel Immunotherapies for Autoimmune Hepatitis. Front Pediatr 2017;5:8. [PMID: 28184367 DOI: 10.3389/fped.2017.00008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
75 Berkovitch G, Cohen S, Lubetzky R, Singer D, Yerushalmy-Feler A. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD. BMC Pediatr 2021;21:63. [PMID: 33541320 DOI: 10.1186/s12887-021-02526-1] [Reference Citation Analysis]
76 Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol 2014;109:994-1004. [PMID: 24842338 DOI: 10.1038/ajg.2014.110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
77 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
78 Rajan D, Greer JB, Regueiro MD, Baidoo L, Binion DG, Herfarth HH, Siegel CA, Hartman DJ, Farraye FA, Koutroubakis IE, Brand MH, Williams ED, Goyal A, Cross RK. IBD LIVE Case Series-Case 6. Inflamm Bowel Dis 2016;22:2754-64. [PMID: 27755273 DOI: 10.1097/MIB.0000000000000941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Mehta P, Furuta GT. Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am 2015;35:413-37. [PMID: 26209893 DOI: 10.1016/j.iac.2015.04.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
80 Xiao J, Zhang R, Chen W, Niu B. An unusual case of acute lower gastrointestinal bleeding due to fungal infection. J Int Med Res 2020;48:300060520967820. [PMID: 33143513 DOI: 10.1177/0300060520967820] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015;16:63-78. [PMID: 25418125 DOI: 10.1517/14656566.2015.981525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
82 Lee WJ, Lee TA, Calip GS, Suda KJ, Briars L, Schumock GT. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:883-91. [PMID: 29562275 DOI: 10.1093/ibd/izx080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Reference Citation Analysis]
85 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
86 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
87 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
88 Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, Sujino T, Miyoshi J, Takabayashi K, Mikami Y, Mizuno S, Wada Y, Yajima T, Naganuma M, Inoue N, Iwao Y, Ogata H, Hasegawa H, Kitagawa Y, Hibi T, Kanai T. Risk and Management of Intra-Abdominal Abscess in Crohn's Disease Treated with Infliximab. Digestion 2014;89:201-8. [DOI: 10.1159/000360618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
89 Czaja AJ. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Dig Dis Sci 2022. [PMID: 35147819 DOI: 10.1007/s10620-021-07378-4] [Reference Citation Analysis]
90 Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis 2014;46:1066-71. [PMID: 25169961 DOI: 10.1016/j.dld.2014.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
91 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
92 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
93 Kim M, Katz S, Green J. Drug Management in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015;13:90-104. [PMID: 25617139 DOI: 10.1007/s11938-014-0039-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
94 Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56. [PMID: 25110252 DOI: 10.1016/j.gtc.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
95 Strobel S, Abreu MT. Update on idiopathic colitides. Curr Opin Gastroenterol 2013;29:60-5. [PMID: 23207597 DOI: 10.1097/MOG.0b013e32835abc93] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Armuzzi A, Ardizzone S, Biancone L, Castiglione F, Danese S, Gionchetti P, Orlando A, Rizzello F, Scribano ML, Vecchi M, Daperno M. Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Disease 2018;50:653-60. [DOI: 10.1016/j.dld.2018.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
97 Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep 2019;21:1. [PMID: 30635807 DOI: 10.1007/s11894-019-0669-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
98 Colombel J, Sandborn WJ, Reinisch W, Peyrin-biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson A, Lau W, Maa J, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther 2018;47:219-28. [DOI: 10.1111/apt.14420] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
99 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
100 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
101 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 13.9] [Reference Citation Analysis]
102 Zeisler B, Hyams JS. Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab. Pediatric Health Med Ther 2015;6:33-40. [PMID: 29388607 DOI: 10.2147/PHMT.S40948] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther 2014; 5(2): 63-76 [PMID: 24868487 DOI: 10.4292/wjgpt.v5.i2.63] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
104 Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, Ben Yehoyada M, Mould DR. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247-2259. [PMID: 25358062 DOI: 10.1097/mib.0000000000000212] [Cited by in Crossref: 170] [Cited by in F6Publishing: 63] [Article Influence: 24.3] [Reference Citation Analysis]
105 Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017;318:1679-86. [PMID: 29114832 DOI: 10.1001/jama.2017.16071] [Cited by in Crossref: 229] [Cited by in F6Publishing: 193] [Article Influence: 45.8] [Reference Citation Analysis]
106 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Reference Citation Analysis]
107 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
108 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
109 Ha CY. Risks of Infection among the Older Inflammatory Bowel Disease Patients. Curr Treat Options Gastro 2014;12:283-91. [DOI: 10.1007/s11938-014-0023-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
110 Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1266-71. [PMID: 29718260 DOI: 10.1093/ibd/izy088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
111 Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB. Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther 2012;36:1049-56. [PMID: 23061548 DOI: 10.1111/apt.12075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
112 Uda A, Kuwabara H, Shimizu S, Iwakiri R, Fushimi K. Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. JGH Open 2020;4:532-40. [PMID: 32514466 DOI: 10.1002/jgh3.12329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Bots S, Gecse K, Barclay M, D'Haens G. Combination Immunosuppression in IBD. Inflamm Bowel Dis 2018;24:539-45. [PMID: 29462391 DOI: 10.1093/ibd/izx065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
114 Scott FI, Osterman MT. Medical management of crohn disease. Clin Colon Rectal Surg 2013;26:67-74. [PMID: 24436652 DOI: 10.1055/s-0033-1348043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
115 Nirmal SA, Gangurde SS, Dumbre PS, Pal SC, Mandal SC. Challenges and opportunities in the treatment of ulcerative colitis. World J Pharmacol 2015; 4(2): 219-226 [DOI: 10.5497/wjp.v4.i2.219] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
117 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
118 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
119 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
120 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
121 Rao Q, Ma GC, Wu H, Li M, Xu W, Wang GJ, Wang D, Zhang CE, Ma ZJ, Zhang ZT. Dendritic cell combination therapy reduces the toxicity of triptolide and ameliorates colitis in murine models. Drug Deliv 2022;29:679-91. [PMID: 35225120 DOI: 10.1080/10717544.2022.2044935] [Reference Citation Analysis]
122 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
123 Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(12): 1956-1980 [DOI: 10.4251/wjgo.v13.i12.1956] [Reference Citation Analysis]
124 Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548 [PMID: 31210708 DOI: 10.3748/wjg.v25.i21.2539] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
125 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
126 Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735-44. [PMID: 24788825 DOI: 10.1002/pds.3621] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
127 Yadav S, Singh S, Harmsen WS, Edakkanambeth Varayil J, Tremaine WJ, Loftus EV Jr. Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc 2015;90:738-46. [PMID: 25963756 DOI: 10.1016/j.mayocp.2015.03.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
128 Mosli MH, Feagan BG. Combination therapy for the treatment of Crohn's disease. Expert Opin Biol Ther 2015;15:1429-42. [PMID: 26211474 DOI: 10.1517/14712598.2015.1065249] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:437-443. [PMID: 28279079 DOI: 10.1080/14740338.2017.1298743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
130 Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1533-1540.e2. [PMID: 30268561 DOI: 10.1016/j.cgh.2018.09.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
131 Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine 2018;101:78-88. [PMID: 27688201 DOI: 10.1016/j.cyto.2016.09.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
132 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
133 Denis M, Roy D, Yeganeh P, Desjardins Y, Varin T, Haddad N, Amre D, Sané A, Garofalo C, Furtos A, Patey N, Delvin E, Tremblay E, Marette A, Beaulieu J, Levy E. Apple peel polyphenols: a key player in the prevention and treatment of experimental inflammatory bowel disease. Clinical Science 2016;130:2217-37. [DOI: 10.1042/cs20160524] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
134 Kim BS, Maverakis E, Alexanian C, Wang JZ, Raychaudhuri SP. Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review. J Cutan Med Surg 2020;24:278-84. [PMID: 32238066 DOI: 10.1177/1203475420914622] [Reference Citation Analysis]
135 Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol 2017;29:84-90. [PMID: 27603297 DOI: 10.1097/MEG.0000000000000735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
136 Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 2021;17:213-23. [PMID: 33686279 DOI: 10.1038/s41584-021-00584-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
137 Song CY, Xu YG, Lu YQ. Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects. J Zhejiang Univ Sci B 2020;21:280-90. [PMID: 32253838 DOI: 10.1631/jzus.B1900607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
138 Cheung M, Khan S, Akerman M, Hung CK, Vennard K, Hristis N, Sultan K. Clinical markers of Crohn’s disease severity and their association with opiate use. J Clin Med Res. 2015;7:33-36. [PMID: 25368699 DOI: 10.14740/jocmr1969w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
139 Ariyaratnam J, Subramanian V. Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis. American Journal of Gastroenterology 2014;109:163-9. [DOI: 10.1038/ajg.2013.451] [Cited by in Crossref: 102] [Cited by in F6Publishing: 81] [Article Influence: 12.8] [Reference Citation Analysis]